Solentim Ltd.. (10/1/19). "Press Release: Dr Mark Truesdale Joins Solentim as New Chief Marketing Officer". Bournemouth.

	Organisation	Solentim Ltd.
	Group	Solentim (Group)
	Organisation 2	Thermo Fisher Scientific Inc. (NYSE: TMO)
	Group	Thermo Fisher (Group)
	Product	Cell Metric™ system
	Product 2	VIPS™ (verified in-situ plate seeding) system
	Person	Truesdale, Mark (Solentim 202003– CEO joined 201910– as Chief Marketing Officer before Thermo Fisher + Genetix)
	Person 2	Figg, Aaron (Solentim 201910 Managing Director)

Solentim, the global leader in cell line development (CLD) instrumentation, is delighted to announce that Dr Mark Truesdale will join the Company as the new Chief Marketing Officer, effective immediately.

Mark brings with him a wealth of experience, most recently seven years at Thermo Fisher Scientific, during which time he held the position of Senior Director of Global Marketing for its Food Protection Business, leading the business unit strategy, product management and tactical marketing teams. Prior to this, Mark spent 14 years with Genetix in a number of roles, including Head of Global Marketing, prior to and through its acquisition by Danaher Corporation.

Upon this appointment Dr Truesdale commented, “Solentim is going from strength to strength as a Company; I very much look forward to applying my knowledge and experience, working closely with the Solentim team, to continue to provide our customers with the best possible offering. I will also be focussing on developing our strategy for the future in cell line development.”

Aaron Figg, Managing Director at Solentim, commented, “Having now reached our tenth year of continuous growth, we are ready to expand our executive team to bring in a wider range of skills and experience that will support further success. It is a tribute to our strength as a Company that we are now able to attract new senior talent such as Mark.”
ENDS
Notes to editors

About Solentim
Solentim is the global leader in enabling accelerated cell line development for new biologic drugs through its proprietary intelligent automation. Solentim’s portfolio of products (VIPS™, Cell Metric® and Cell Metric® CLD) enables customers to establish a simple to use and completely integrated workflow, revolutionising single cell cloning and providing documented daily whole well image assurance of monoclonality for FDA and other regulatory bodies. Solentim works with the world’s top 10 pharmaceutical companies and has a customer installed base of several hundred instruments. It also has established strategic partnerships with ATUM and Valitacell. In 2018, Solentim was the recipient of two highly prestigious Queen’s Awards for Enterprise and was also named in the Deloitte UK Technology Fast 50. Visit www.solentim.com for more information.
For further information, contact:

Corporate Contact:
Solentim Ltd
Dr Ian Taylor, Chief Commercial Officer
T: +44 (0)1202 051813
E: ian.taylor@solentim.com

PR Contact:
Emma Pickup / Sophie Protheroe / Juliette Craggs
Sciad Communications Ltd
T: +44 (0)20 3755 0571
E: solentim@sciad.com

Record changed: 2023-06-05